Mizuho Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear downgraded ACADIA Pharmaceuticals (ACAD) from Buy to Neutral and reduced the price target from $39 to $25, indicating a more cautious outlook on the company's stock.
March 12, 2024 | 9:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ACADIA Pharmaceuticals was downgraded by Mizuho from Buy to Neutral, with a price target reduction from $39 to $25, reflecting a more conservative view on the stock's future performance.
The downgrade from Buy to Neutral by a significant analyst like Mizuho, coupled with a substantial reduction in the price target, suggests a less optimistic outlook on ACADIA Pharmaceuticals' stock. This could lead to a negative short-term impact on the stock price as investors adjust their expectations based on this new analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100